AU1097500A - Human gene expressed in cancers of prostate, bladder, pancreas and colon, 36p1a6 - Google Patents

Human gene expressed in cancers of prostate, bladder, pancreas and colon, 36p1a6 Download PDF

Info

Publication number: AU1097500A
Authority: AU; Australia
Prior art keywords: cancer; protein; polynucleotide; mrna; prostate
Prior art date: 1998-10-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU10975/00A

Other languages

English (en)

Inventor

Daniel E. Afar

Rene S. Hubert

Stephen Chappell Mitchell

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Agensys Inc

Original Assignee

Urogenesys Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-10-02

Filing date

1999-10-02

Publication date

2000-04-26

1999-10-02 Application filed by Urogenesys Inc filed Critical Urogenesys Inc

2000-04-26 Publication of AU1097500A publication Critical patent/AU1097500A/en

2002-01-03 Assigned to AGENSYS, INC. reassignment AGENSYS, INC. Amend patent request/document other than specification (104) Assignors: UROGENESYS, INC.

Status Abandoned legal-status Critical Current

Links

108090000623 proteins and genes Proteins 0.000 title claims description 227
206010028980 Neoplasm Diseases 0.000 title claims description 129
210000002307 prostate Anatomy 0.000 title description 50
210000001072 colon Anatomy 0.000 title description 23
210000003932 urinary bladder Anatomy 0.000 title description 19
210000000496 pancreas Anatomy 0.000 title description 16
102000004169 proteins and genes Human genes 0.000 claims description 147
238000000034 method Methods 0.000 claims description 92
239000002157 polynucleotide Substances 0.000 claims description 76
102000040430 polynucleotide Human genes 0.000 claims description 76
108091033319 polynucleotide Proteins 0.000 claims description 76
230000014509 gene expression Effects 0.000 claims description 71
201000011510 cancer Diseases 0.000 claims description 58
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 55
239000002299 complementary DNA Substances 0.000 claims description 54
239000000523 sample Substances 0.000 claims description 49
206010060862 Prostate cancer Diseases 0.000 claims description 48
108020004999 messenger RNA Proteins 0.000 claims description 47
210000001519 tissue Anatomy 0.000 claims description 47
239000012634 fragment Substances 0.000 claims description 43
108090000765 processed proteins & peptides Proteins 0.000 claims description 36
238000003556 assay Methods 0.000 claims description 34
102000004196 processed proteins & peptides Human genes 0.000 claims description 34
239000000203 mixture Substances 0.000 claims description 30
229920001184 polypeptide Polymers 0.000 claims description 29
125000003275 alpha amino acid group Chemical group 0.000 claims description 21
230000027455 binding Effects 0.000 claims description 18
230000002401 inhibitory effect Effects 0.000 claims description 18
108020004635 Complementary DNA Proteins 0.000 claims description 17
125000003729 nucleotide group Chemical group 0.000 claims description 17
238000011282 treatment Methods 0.000 claims description 17
230000000692 anti-sense effect Effects 0.000 claims description 16
238000009396 hybridization Methods 0.000 claims description 15
238000013518 transcription Methods 0.000 claims description 15
230000035897 transcription Effects 0.000 claims description 15
230000002163 immunogen Effects 0.000 claims description 14
239000002773 nucleotide Substances 0.000 claims description 13
239000003550 marker Substances 0.000 claims description 12
206010061535 Ovarian neoplasm Diseases 0.000 claims description 11
238000013519 translation Methods 0.000 claims description 11
150000001413 amino acids Chemical class 0.000 claims description 10
230000000295 complement effect Effects 0.000 claims description 10
102000053642 Catalytic RNA Human genes 0.000 claims description 9
108090000994 Catalytic RNA Proteins 0.000 claims description 9
239000012472 biological sample Substances 0.000 claims description 9
108091092562 ribozyme Proteins 0.000 claims description 9
206010061902 Pancreatic neoplasm Diseases 0.000 claims description 8
208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 8
208000029742 colonic neoplasm Diseases 0.000 claims description 8
239000013612 plasmid Substances 0.000 claims description 8
238000012360 testing method Methods 0.000 claims description 8
206010008342 Cervix carcinoma Diseases 0.000 claims description 7
208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 7
201000010881 cervical cancer Diseases 0.000 claims description 7
239000013604 expression vector Substances 0.000 claims description 6
229960005486 vaccine Drugs 0.000 claims description 6
206010005003 Bladder cancer Diseases 0.000 claims description 5
206010033128 Ovarian cancer Diseases 0.000 claims description 5
206010009944 Colon cancer Diseases 0.000 claims description 4
238000011161 development Methods 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
201000002528 pancreatic cancer Diseases 0.000 claims description 4
208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
201000005112 urinary bladder cancer Diseases 0.000 claims description 3
238000010839 reverse transcription Methods 0.000 claims description 2
239000002787 antisense oligonuctleotide Substances 0.000 claims 1
238000012258 culturing Methods 0.000 claims 1
238000003259 recombinant expression Methods 0.000 claims 1
235000018102 proteins Nutrition 0.000 description 131
210000004027 cell Anatomy 0.000 description 91
230000001225 therapeutic effect Effects 0.000 description 38
239000013598 vector Substances 0.000 description 22
108010072866 Prostate-Specific Antigen Proteins 0.000 description 20
102000007066 Prostate-Specific Antigen Human genes 0.000 description 20
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
201000010099 disease Diseases 0.000 description 19
108020004414 DNA Proteins 0.000 description 18
238000010240 RT-PCR analysis Methods 0.000 description 18
238000004458 analytical method Methods 0.000 description 18
238000001514 detection method Methods 0.000 description 18
108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
150000007523 nucleic acids Chemical class 0.000 description 17
102000039446 nucleic acids Human genes 0.000 description 16
108020004707 nucleic acids Proteins 0.000 description 16
238000013459 approach Methods 0.000 description 15
241000699670 Mus sp. Species 0.000 description 12
235000001014 amino acid Nutrition 0.000 description 12
238000005516 engineering process Methods 0.000 description 12
239000000047 product Substances 0.000 description 12
238000006243 chemical reaction Methods 0.000 description 11
230000006870 function Effects 0.000 description 11
210000001672 ovary Anatomy 0.000 description 11
210000002966 serum Anatomy 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
210000004072 lung Anatomy 0.000 description 10
101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 9
229940024606 amino acid Drugs 0.000 description 9
230000000694 effects Effects 0.000 description 9
230000012010 growth Effects 0.000 description 9
238000002965 ELISA Methods 0.000 description 8
102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 8
238000000636 Northern blotting Methods 0.000 description 8
230000003321 amplification Effects 0.000 description 8
210000003679 cervix uteri Anatomy 0.000 description 8
238000003745 diagnosis Methods 0.000 description 8
238000003384 imaging method Methods 0.000 description 8
238000002955 isolation Methods 0.000 description 8
238000003199 nucleic acid amplification method Methods 0.000 description 8
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 7
108091026890 Coding region Proteins 0.000 description 7
241001529936 Murinae Species 0.000 description 7
108091034117 Oligonucleotide Proteins 0.000 description 7
208000004403 Prostatic Hyperplasia Diseases 0.000 description 7
108020004511 Recombinant DNA Proteins 0.000 description 7
239000000427 antigen Substances 0.000 description 7
108091007433 antigens Proteins 0.000 description 7
102000036639 antigens Human genes 0.000 description 7
210000004443 dendritic cell Anatomy 0.000 description 7
238000010195 expression analysis Methods 0.000 description 7
108020001507 fusion proteins Proteins 0.000 description 7
102000037865 fusion proteins Human genes 0.000 description 7
210000004962 mammalian cell Anatomy 0.000 description 7
238000007726 management method Methods 0.000 description 7
230000001105 regulatory effect Effects 0.000 description 7
238000006467 substitution reaction Methods 0.000 description 7
101000921245 Homo sapiens ETS homologous factor Proteins 0.000 description 6
101000877379 Homo sapiens ETS-related transcription factor Elf-3 Proteins 0.000 description 6
206010027476 Metastases Diseases 0.000 description 6
238000011579 SCID mouse model Methods 0.000 description 6
108091023040 Transcription factor Proteins 0.000 description 6
102000040945 Transcription factor Human genes 0.000 description 6
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
230000006907 apoptotic process Effects 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
230000034994 death Effects 0.000 description 6
231100000517 death Toxicity 0.000 description 6
230000003053 immunization Effects 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
210000004881 tumor cell Anatomy 0.000 description 6
241000701447 unidentified baculovirus Species 0.000 description 6
102000040848 ETS family Human genes 0.000 description 5
108091071901 ETS family Proteins 0.000 description 5
102100032025 ETS homologous factor Human genes 0.000 description 5
238000012408 PCR amplification Methods 0.000 description 5
102000016157 Pointed domains Human genes 0.000 description 5
108050004610 Pointed domains Proteins 0.000 description 5
229940022399 cancer vaccine Drugs 0.000 description 5
238000009566 cancer vaccine Methods 0.000 description 5
230000001413 cellular effect Effects 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
238000010367 cloning Methods 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
238000002649 immunization Methods 0.000 description 5
230000003834 intracellular effect Effects 0.000 description 5
ZKUKMWMSYCIYRD-ZXFNITATSA-N lenampicillin Chemical compound O1C(=O)OC(COC(=O)[C@H]2C(S[C@H]3N2C([C@H]3NC(=O)[C@H](N)C=2C=CC=CC=2)=O)(C)C)=C1C ZKUKMWMSYCIYRD-ZXFNITATSA-N 0.000 description 5
230000009401 metastasis Effects 0.000 description 5
206010061289 metastatic neoplasm Diseases 0.000 description 5
210000004940 nucleus Anatomy 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
238000012552 review Methods 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
238000001262 western blot Methods 0.000 description 5
201000009030 Carcinoma Diseases 0.000 description 4
102100035079 ETS-related transcription factor Elf-3 Human genes 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 4
102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 4
-1 SISBA Proteins 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
238000000246 agarose gel electrophoresis Methods 0.000 description 4
125000000539 amino acid group Chemical group 0.000 description 4
239000003098 androgen Substances 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
231100000504 carcinogenesis Toxicity 0.000 description 4
239000003814 drug Substances 0.000 description 4
210000000987 immune system Anatomy 0.000 description 4
238000000099 in vitro assay Methods 0.000 description 4
238000005462 in vivo assay Methods 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
239000012528 membrane Substances 0.000 description 4
208000010658 metastatic prostate carcinoma Diseases 0.000 description 4
238000010369 molecular cloning Methods 0.000 description 4
230000002018 overexpression Effects 0.000 description 4
238000002823 phage display Methods 0.000 description 4
230000000069 prophylactic effect Effects 0.000 description 4
208000023958 prostate neoplasm Diseases 0.000 description 4
238000000746 purification Methods 0.000 description 4
238000011002 quantification Methods 0.000 description 4
238000011160 research Methods 0.000 description 4
230000001177 retroviral effect Effects 0.000 description 4
230000019491 signal transduction Effects 0.000 description 4
210000000813 small intestine Anatomy 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
208000005623 Carcinogenesis Diseases 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
102000005720 Glutathione transferase Human genes 0.000 description 3
108010070675 Glutathione transferase Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241000238631 Hexapoda Species 0.000 description 3
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
108060001084 Luciferase Proteins 0.000 description 3
239000005089 Luciferase Substances 0.000 description 3
102000043136 MAP kinase family Human genes 0.000 description 3
108091054455 MAP kinase family Proteins 0.000 description 3
102000043129 MHC class I family Human genes 0.000 description 3
108091054437 MHC class I family Proteins 0.000 description 3
101710120463 Prostate stem cell antigen Proteins 0.000 description 3
102100036735 Prostate stem cell antigen Human genes 0.000 description 3
239000013614 RNA sample Substances 0.000 description 3
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
230000001640 apoptogenic effect Effects 0.000 description 3
230000003385 bacteriostatic effect Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
210000000988 bone and bone Anatomy 0.000 description 3
230000036952 cancer formation Effects 0.000 description 3
238000002512 chemotherapy Methods 0.000 description 3
230000001086 cytosolic effect Effects 0.000 description 3
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
230000004069 differentiation Effects 0.000 description 3
210000002472 endoplasmic reticulum Anatomy 0.000 description 3
238000001415 gene therapy Methods 0.000 description 3
238000010324 immunological assay Methods 0.000 description 3
238000007901 in situ hybridization Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
230000002452 interceptive effect Effects 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
239000003446 ligand Substances 0.000 description 3
210000001165 lymph node Anatomy 0.000 description 3
239000000463 material Substances 0.000 description 3
238000005259 measurement Methods 0.000 description 3
239000002609 medium Substances 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000010606 normalization Methods 0.000 description 3
230000002611 ovarian Effects 0.000 description 3
238000004393 prognosis Methods 0.000 description 3
201000007094 prostatitis Diseases 0.000 description 3
230000009257 reactivity Effects 0.000 description 3
238000012163 sequencing technique Methods 0.000 description 3
239000000243 solution Substances 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
230000002103 transcriptional effect Effects 0.000 description 3
238000001890 transfection Methods 0.000 description 3
238000012546 transfer Methods 0.000 description 3
239000004474 valine Substances 0.000 description 3
102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
206010061728 Bone lesion Diseases 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
230000004568 DNA-binding Effects 0.000 description 2
241000702421 Dependoparvovirus Species 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
108091060211 Expressed sequence tag Proteins 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
102100039554 Galectin-8 Human genes 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
101000608769 Homo sapiens Galectin-8 Proteins 0.000 description 2
108700005091 Immunoglobulin Genes Proteins 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
241000713666 Lentivirus Species 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
206010027452 Metastases to bone Diseases 0.000 description 2
108091061960 Naked DNA Proteins 0.000 description 2
206010061309 Neoplasm progression Diseases 0.000 description 2
108700020796 Oncogene Proteins 0.000 description 2
108091093037 Peptide nucleic acid Proteins 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
108010059712 Pronase Proteins 0.000 description 2
108010076504 Protein Sorting Signals Proteins 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
241000256251 Spodoptera frugiperda Species 0.000 description 2
230000024932 T cell mediated immunity Effects 0.000 description 2
108700005077 Viral Genes Proteins 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
238000011319 anticancer therapy Methods 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
238000001574 biopsy Methods 0.000 description 2
201000001531 bladder carcinoma Diseases 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
238000010804 cDNA synthesis Methods 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000002738 chelating agent Substances 0.000 description 2
239000000470 constituent Substances 0.000 description 2
210000000172 cytosol Anatomy 0.000 description 2
238000002405 diagnostic procedure Methods 0.000 description 2
238000010494 dissociation reaction Methods 0.000 description 2
230000005593 dissociations Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000000284 extract Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
238000001476 gene delivery Methods 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
102000044533 human ELF3 Human genes 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
230000004727 humoral immunity Effects 0.000 description 2
210000004408 hybridoma Anatomy 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
238000002991 immunohistochemical analysis Methods 0.000 description 2
238000001114 immunoprecipitation Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000009545 invasion Effects 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
150000002632 lipids Chemical group 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
108010082117 matrigel Proteins 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
230000001394 metastastic effect Effects 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
230000003278 mimic effect Effects 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
238000007899 nucleic acid hybridization Methods 0.000 description 2
230000001582 osteoblastic effect Effects 0.000 description 2
239000008188 pellet Substances 0.000 description 2
210000005259 peripheral blood Anatomy 0.000 description 2
239000011886 peripheral blood Substances 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
238000012545 processing Methods 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
230000004850 protein–protein interaction Effects 0.000 description 2
238000002601 radiography Methods 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
238000001959 radiotherapy Methods 0.000 description 2
230000000754 repressing effect Effects 0.000 description 2
238000012216 screening Methods 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
238000002864 sequence alignment Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000010186 staining Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000001629 suppression Effects 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
230000008685 targeting Effects 0.000 description 2
230000009261 transgenic effect Effects 0.000 description 2
238000011277 treatment modality Methods 0.000 description 2
230000005740 tumor formation Effects 0.000 description 2
239000000439 tumor marker Substances 0.000 description 2
230000005751 tumor progression Effects 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
208000010570 urinary bladder carcinoma Diseases 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
238000005406 washing Methods 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
101150113082 A6 gene Proteins 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
102100032187 Androgen receptor Human genes 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
108010047041 Complementarity Determining Regions Proteins 0.000 description 1
102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 1
108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 1
102100023033 Cyclic AMP-dependent transcription factor ATF-2 Human genes 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
229940021995 DNA vaccine Drugs 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
101150106035 EHF gene Proteins 0.000 description 1
UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
208000000666 Fowlpox Diseases 0.000 description 1
108010046569 Galectins Proteins 0.000 description 1
102000007563 Galectins Human genes 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
101000974934 Homo sapiens Cyclic AMP-dependent transcription factor ATF-2 Proteins 0.000 description 1
101000997829 Homo sapiens Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
102000004157 Hydrolases Human genes 0.000 description 1
108090000604 Hydrolases Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
102000043131 MHC class II family Human genes 0.000 description 1
108091054438 MHC class II family Proteins 0.000 description 1
208000035346 Margins of Excision Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
108700019961 Neoplasm Genes Proteins 0.000 description 1
102000048850 Neoplasm Genes Human genes 0.000 description 1
208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
108090000189 Neuropeptides Proteins 0.000 description 1
102000003797 Neuropeptides Human genes 0.000 description 1
108010077850 Nuclear Localization Signals Proteins 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
101150102573 PCR1 gene Proteins 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
102100025067 Potassium voltage-gated channel subfamily H member 4 Human genes 0.000 description 1
101710163352 Potassium voltage-gated channel subfamily H member 4 Proteins 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
108091034057 RNA (poly(A)) Proteins 0.000 description 1
238000002123 RNA extraction Methods 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
206010066901 Treatment failure Diseases 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
238000002679 ablation Methods 0.000 description 1
238000010317 ablation therapy Methods 0.000 description 1
239000008272 agar Substances 0.000 description 1
238000013019 agitation Methods 0.000 description 1
UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
108010080146 androgen receptors Proteins 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000006023 anti-tumor response Effects 0.000 description 1
210000000612 antigen-presenting cell Anatomy 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
210000004436 artificial bacterial chromosome Anatomy 0.000 description 1
210000001106 artificial yeast chromosome Anatomy 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
238000002820 assay format Methods 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
210000000270 basal cell Anatomy 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
239000003124 biologic agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
108700021042 biotin binding protein Proteins 0.000 description 1
102000043871 biotin binding protein Human genes 0.000 description 1
239000000872 buffer Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
239000012830 cancer therapeutic Substances 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
238000002701 cell growth assay Methods 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000002975 chemoattractant Substances 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
239000003636 conditioned culture medium Substances 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
238000002716 delivery method Methods 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000007865 diluting Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 1
208000023965 endometrium neoplasm Diseases 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
230000037433 frameshift Effects 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000003208 gene overexpression Methods 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
210000003128 head Anatomy 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
102000043706 human EHF Human genes 0.000 description 1
210000002758 humerus Anatomy 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
229940124452 immunizing agent Drugs 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
230000002055 immunohistochemical effect Effects 0.000 description 1
238000012151 immunohistochemical method Methods 0.000 description 1
239000012535 impurity Substances 0.000 description 1
APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
229940055742 indium-111 Drugs 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000010189 intracellular transport Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
238000009630 liquid culture Methods 0.000 description 1
238000004020 luminiscence type Methods 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
239000006166 lysate Substances 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
230000001617 migratory effect Effects 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
230000009149 molecular binding Effects 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
230000035772 mutation Effects 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
210000003739 neck Anatomy 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000011580 nude mouse model Methods 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
230000011164 ossification Effects 0.000 description 1
230000000010 osteolytic effect Effects 0.000 description 1
210000004923 pancreatic tissue Anatomy 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000013610 patient sample Substances 0.000 description 1
210000004197 pelvis Anatomy 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
238000009520 phase I clinical trial Methods 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
231100000316 potential neurotoxicity Toxicity 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000037452 priming Effects 0.000 description 1
229940030749 prostate cancer vaccine Drugs 0.000 description 1
210000005267 prostate cell Anatomy 0.000 description 1
208000017497 prostate disease Diseases 0.000 description 1
238000011471 prostatectomy Methods 0.000 description 1
238000002331 protein detection Methods 0.000 description 1
230000000722 protumoral effect Effects 0.000 description 1
238000011472 radical prostatectomy Methods 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
239000013074 reference sample Substances 0.000 description 1
230000004044 response Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
230000007017 scission Effects 0.000 description 1
210000000582 semen Anatomy 0.000 description 1
210000001625 seminal vesicle Anatomy 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
241000894007 species Species 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
238000009121 systemic therapy Methods 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
238000010323 transrectal needle biopsy Methods 0.000 description 1
230000004565 tumor cell growth Effects 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
210000003708 urethra Anatomy 0.000 description 1
206010046459 urethral obstruction Diseases 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
201000010653 vesiculitis Diseases 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000011179 visual inspection Methods 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

AU10975/00A 1998-10-02 1999-10-02 Human gene expressed in cancers of prostate, bladder, pancreas and colon, 36p1a6 Abandoned AU1097500A (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US10274498P	1998-10-02	1998-10-02
US60102744		1998-10-02
US14644799P	1999-07-29	1999-07-29
US60146447		1999-07-29
PCT/US1999/022576 WO2000020584A2 (fr)	1998-10-02	1999-10-02	Gene human 36p1a6 exprime dans le cancer de la prostate, de la vessie, du pancreas et du colon

Publications (1)

Publication Number	Publication Date
AU1097500A true AU1097500A (en)	2000-04-26

Family

ID=26799687

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU10975/00A Abandoned AU1097500A (en)	1998-10-02	1999-10-02	Human gene expressed in cancers of prostate, bladder, pancreas and colon, 36p1a6

Country Status (5)

Country	Link
EP (1)	EP1117794A2 (fr)
AU (1)	AU1097500A (fr)
CA (1)	CA2344552A1 (fr)
IL (1)	IL142310A0 (fr)
WO (1)	WO2000020584A2 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6887660B2 (en) *	1997-02-25	2005-05-03	Corixa Corporation	Compounds for immunodiagnosis of prostate cancer and methods for their use
EP1005546A2 (fr) *	1997-02-25	2000-06-07	Corixa Corporation	Composes permettant l'immunotherapie du cancer de la prostate et procedes concernant leur utilisation
WO2000004149A2 (fr) *	1998-07-14	2000-01-27	Corixa Corporation	Compositions et methodes de therapie et de diagnostic du cancer de la prostate
CA2314677A1 (fr) *	1998-01-21	1999-07-29	Axys Pharmaceuticals, Inc.	Genes associes a l'asthme
DE69943020D1 (de) *	1998-06-01	2011-01-20	Agensys Inc	Tumorantigen verwendbar in der diagnose und therapie von prostata und dickdarm-krebs

1999
- 1999-10-02 WO PCT/US1999/022576 patent/WO2000020584A2/fr not_active Ceased
- 1999-10-02 AU AU10975/00A patent/AU1097500A/en not_active Abandoned
- 1999-10-02 CA CA002344552A patent/CA2344552A1/fr not_active Abandoned
- 1999-10-02 EP EP99954686A patent/EP1117794A2/fr not_active Withdrawn
- 1999-10-02 IL IL14231099A patent/IL142310A0/xx unknown

Also Published As

Publication number	Publication date
EP1117794A2 (fr)	2001-07-25
WO2000020584A3 (fr)	2000-07-06
WO2000020584A9 (fr)	2000-08-31
CA2344552A1 (fr)	2000-04-13
IL142310A0 (en)	2002-03-10
WO2000020584A2 (fr)	2000-04-13

Publication	Publication Date	Title
US7968283B2 (en)	2011-06-28	Gene expressed in prostate cancer
US8003758B2 (en)	2011-08-23	BPC-1: a secreted brain-specific protein expressed and secreted by prostate and bladder cancer cells
US7008779B1 (en)	2006-03-07	PHELIX: a testis-specific protein expressed in cancer
US6652859B1 (en)	2003-11-25	PTANS: testis specific proteins expressed in prostate cancer
AU2006225260B2 (en)	2008-11-20	Gene expressed in prostate cancer
AU1097500A (en)	2000-04-26	Human gene expressed in cancers of prostate, bladder, pancreas and colon, 36p1a6
WO2000020638A9 (fr)	2000-10-05	Procedes et compositions pour le diagnostic et la therapie du cancer de la prostate

Legal Events

Date	Code	Title	Description
2002-01-03	TC	Change of applicant's name (sec. 104)	Owner name: AGENSYS, INC. Free format text: FORMER NAME: UROGENESYS, INC.
2004-05-06	MK5	Application lapsed section 142(2)(e) - patent request and compl. specification not accepted

Date

Code

Title

Description

2002-01-03

Change of applicant's name (sec. 104)

Owner name: AGENSYS, INC.

Free format text: FORMER NAME: UROGENESYS, INC.

2004-05-06

MK5

Application lapsed section 142(2)(e) - patent request and compl. specification not accepted